Top 8 Trials From 2021 in Breast Cancer

home / publications / supplements / top-2021-abstracts-in-breast-cancer

The Top 2021 Abstracts in Breast Cancer publication provides expert insights on groundbreaking abstracts in breast cancer, with a focus on HER2-positive breast cancer treatment that were presented at medical meetings throughout 2021.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®


Debu Tripathy, MD, of MD Anderson Cancer Center

Dr. Tripathy on the NALA Trial in HER2+ Breast Cancer With Brain Metastases

Debu Tripathy, MD,
March 24th 2022
Video

Debu Tripathy, MD, discusses the implications of results from the phase 3 NALA trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Komal Jhaveri, MD, FACP, of Memorial Sloan Kettering Cancer Center

Dr. Jhaveri on the TUXEDO-1 Trial in HER2+ Breast Cancer With Brain Metastases

Komal Jhaveri, MD, FACP
March 23rd 2022
Video

Komal Jhaveri, MD, FACP, discusses the implications of the phase 2 TUXEDO-1 trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Tiffany A. Traina, MD, of Memorial Sloan Kettering Cancer Center

Dr. Traina on the Effects of Elacestrant in ER+, HER2- Breast Cancer

Tiffany A. Traina, MD
March 21st 2022
Video

Tiffany A. Traina, MD, discusses the implications of the phase 3 EMERALD trial in advanced estrogen receptor–positive, HER2-negative breast cancer.

Komal Jhaveri, MD, FACP, of Memorial Sloan Kettering Cancer Center

Dr. Jhaveri on Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

Komal Jhaveri, MD, FACP
March 21st 2022
Video

Komal Jhaveri, MD, FACP, discusses the implications of data from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Ajay Dhakal, MBBS, of University of Rochester Medical Center

Top 8 Trials From 2021 in Breast Cancer

OncLive Staff
March 16th 2022
Article

Leading oncologists in breast cancer share their perspectives on the biggest abstracts that were presented throughout 2021 .

Debasish Tripathy, MD

Data With Antibody-Drug Conjugates and TKIs Impress in HER2+ Breast Cancer

Caroline Seymour
February 17th 2022
Article

Debasish Tripathy, MD, provides perspective on some of the key data sets that were presented and published in 2021 in HER2-positive breast cancer.